Myelodysplastic Syndromes, Version 2.2015

Restricted access

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 234 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 119 119 23
PDF Downloads 22 22 2
EPUB Downloads 0 0 0